Sign inJoin waitlistJoin the waitlist

Maria Velez

Professor - Clinical · Louisiana State University School of Medicine

Credentials: · · · · ·

History

Louisiana State University School of Medicine
Present
Louisiana State University School of Medicine
Present

Pediatric Hematology-Oncology
1990–1991
University Pediatric Hospital
1987–1990
University of Puerto Rico School of Medicine
1983–1987

Research

Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth
Cancer Research · 1994 · 115 citations
1 alpha, 25-dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24-5531) modulation of insulin-like growth factor-binding protein-3 and induction of differentiation and…
The Journal of Clinical Endocrinology & Metabolism · 1996 · First of 7 authors · 22 citations
Langerhans' cell histiocytosis
Review · Orthopedic Clinics of North America · 1996 · First of 2 authors · 21 citations

LH
Lee Helman
3 papers
RW
Rajasekharan Warrier
2 papers
John Letterio
1 paper
SH
Steven Hirschfeld
1 paper

Clinical trials

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2028
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2030
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2031
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2029